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Pathogens with multiple strains present a challenge for vaccine design, as polyvalent vaccines may 
only be effective against some strains of the pathogen. In addition, some bacteria such as 
Streptococcus pneumonia, may recurrently and asymptomatically colonize the nasopharynx in a 
carrier state which is necessary for transmission. Identifying vaccine efficacy against this carrier 
state is important. Because of the potential for individual strain colonization to be cleared and then 
recur, longitudinal sampling provides the best measure of vaccine efficacy; however, such sampling 
is prohibitively invasive for most studies. In a recent paper published in Biometrics, M. Elizabeth 
Halloran (Vaccine and Infectious Disease Division) and collaborators Kari Auranen and Hanna 
Rinta-Kokko (National Institute for Health and Welfare, Finland), describe a framework to estimate 
strain-specific and aggregate vaccine efficacy for pathogens which can be acquired and carried 
repeatedly. 
The team developed two models of colonization and competition with multiple strains of a 
pathogen.  In Model A, an individual may be susceptible, colonized by either strain, or co-colonized 
by both strains. Transition between any of these colonization states is associated with a transition 
hazard, which is the likelihood of a patient in any given state transitioning to a different state, e.g. 
from colonization with strain 1 to clearance. Model B is similar, however, it does not allow for co-
colonization of the patient. Model A led to the derivation of two estimands of vaccine efficacy; one at 
an individual level, and one at a population level. For both of these estimands, total vaccine efficacy 
is a weighted average of the strain-specific efficacies, and they are similar when co-colonization is 
rare and competition between strains is equivalent. 
The team used these estimands to re-examine the vaccine efficacy against nasopharyngeal 
colonization in infants from two polyvalent pneumococcal vaccine studies based on a single 
colonization measurement. For both of these studies, vaccine efficacy was approximately 0.4-0.8 for 
each vaccine strain. This result is slightly higher than estimates based on a simple odds ratio 
measurement which, unlike the model presented in this study, does not account for time-at-risk of 
colonization. Interestingly, vaccine efficacy for non-vaccine strains was negative, suggesting that 
replacement colonization by these strains may occur as competition by vaccine strains is reduced.   
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This study presents a framework to estimate the efficacy of vaccination against colonization. 
Importantly, the models described in this study take into account whether or not an individual is 
susceptible to colonization, and by which strains. Future development of this work will focus on 
unequal competition between strains, changes in rates of colonization over time, and differential 
responses to vaccination. 
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Schematic of the two models of bacterial 
colonization. Model A (top) describes a system 
which allows for co-colonization, while Model 
B (bottom) allows only single colonization. 
Black arrows indicate the allowed transitions 
between colonization states. 
 
